Irbesartan Medley

Irbesartan, the active ingredient in Irbesartan Medley, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It works by selectively blocking AT1 receptors, leading to vasodilation and reduced aldosterone secretion, thereby lowering blood pressure and offering renal protection in patients with hypertension and diabetic kidney disease.

GNH USA supplies Irbesartan Medley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union pharmaceutical standards and is distributed through regulated channels to ensure quality and safety.

Irbesartan is used to treat conditions related to the renin‑angiotensin system, primarily hypertension and kidney disease associated with diabetes.

Hypertension: Reduces systolic and diastolic blood pressure in patients with essential hypertension. Diabetic nephropathy: Slows progression of kidney damage in type 2 diabetes. Chronic kidney disease associated with diabetes: Provides renal protection and helps preserve glomerular filtration rate.

Irbesartan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: Light‑headed sensation, especially after standing. - Headache: Mild to moderate cranial pain. - Fatigue: Generalized tiredness. - Hyperkalaemia: Elevated serum potassium levels.

Serious or Rare Side Effects: - Angioedema: Swelling of face, lips, tongue or airway. - Severe hypotension: Marked drop in blood pressure causing faintness. - Hepatic injury: Elevated liver enzymes or hepatitis.

When prescribing Irbesartan, several safety considerations are recommended.

Blood pressure monitoring: Check regularly to ensure therapeutic target is reached. Renal function assessment: Measure serum creatinine and eGFR before and during therapy. Serum potassium surveillance: Monitor potassium levels, especially when combined with potassium‑sparing agents. Pregnancy contraindication: Avoid use in pregnancy due to fetal toxicity (Category D). Caution in hepatic impairment: Adjust dose or monitor closely in patients with liver disease. Store at room temperature: Keep below 25 °C in original packaging, protect from moisture.

Irbesartan can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Potassium‑sparing diuretics: May cause dangerous hyperkalaemia. - ACE inhibitors or aliskiren: Combined use can lead to excessive renal dysfunction and hypotension. - Lithium: Increases lithium concentrations, risking toxicity. - NSAIDs: Heighten risk of renal impairment and reduced antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: May enhance antihypertensive effect, requiring dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): Can raise irbesartan plasma levels. - Rifampin: May lower irbesartan concentrations, reducing efficacy. - Other antihypertensives (beta‑blockers, calcium channel blockers): Additive blood pressure lowering, monitor for hypotension.